Pharmaceutical The biggest M&A deal announced last week was Merck & Co’s $2.75 billion buy of VelosBio, while Sanofi’s acquisition of Kiadis was notable because the latter company’s future was in doubt just a year ago. Elsewhere, Bristol Myers Squibb had a major pipeline breakthrough and a US Food and Drug Administration briefing document on the Alzherimer’s candidate aducacumab sent shares in Biogen spiralling, even if a committee vote 6 November 2020